141 related articles for article (PubMed ID: 9703255)
21. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
Aprile G; Mazzer M; Moroso S; Puglisi F
Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
[TBL] [Abstract][Full Text] [Related]
22. ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine.
Magné N; Fischel JL; Dubreuil A; Formento P; Ciccolini J; Formento JL; Tiffon C; Renée N; Marchetti S; Etienne MC; Milano G
Clin Cancer Res; 2003 Oct; 9(13):4735-42. PubMed ID: 14581344
[TBL] [Abstract][Full Text] [Related]
23. [Pharmacokinetic comparison of capecitabine and 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR)].
Minami H; Ebi H
Gan To Kagaku Ryoho; 2005 Dec; 32(13):2053-7. PubMed ID: 16352928
[TBL] [Abstract][Full Text] [Related]
24. The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
Temmink OH; Prins HJ; van Gelderop E; Peters GJ
Br J Cancer; 2007 Jan; 96(1):61-6. PubMed ID: 17179993
[TBL] [Abstract][Full Text] [Related]
25. Investigation of 5-FU disposition after oral administration of capecitabine, a triple-prodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5-FU exposures in the tumour tissue between human and xenograft model.
Tsukamoto Y; Kato Y; Ura M; Horii I; Ishikawa T; Ishitsuka H; Sugiyama Y
Biopharm Drug Dispos; 2001 Jan; 22(1):1-14. PubMed ID: 11745902
[TBL] [Abstract][Full Text] [Related]
26. Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889.
Endo M; Miwa M; Eda H; Ura M; Tanimura H; Ishikawa T; Miyazaki-Nose T; Hattori K; Shimma N; Yamada-Okabe H; Ishitsuka H
Int J Cancer; 2003 Sep; 106(5):799-805. PubMed ID: 12866042
[TBL] [Abstract][Full Text] [Related]
27. Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes.
Yasuno H; Kurasawa M; Yanagisawa M; Sato Y; Harada N; Mori K
Oncol Rep; 2013 Feb; 29(2):451-8. PubMed ID: 23229803
[TBL] [Abstract][Full Text] [Related]
28. A comparative study of the antitumor activities of 5'-deoxy-5-fluorouridine and its prodrug trimethoxybenzoyl-5'-deoxy-5-fluorocytidine (Ro09-1390) on human digestive organ cancer xenograft lines transplanted into nude mice.
Nio Y; Kimura H; Tsubono M; Tseng CC; Kawabata K; Masai Y; Hayashi H; Araya S; Meyer C; Fukumoto M
Anticancer Drugs; 1992 Aug; 3(4):387-93. PubMed ID: 1421435
[TBL] [Abstract][Full Text] [Related]
29. A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma.
Vainchtein LD; Rosing H; Schellens JH; Beijnen JH
Biomed Chromatogr; 2010 Apr; 24(4):374-86. PubMed ID: 19650151
[TBL] [Abstract][Full Text] [Related]
30. Forced expression of cytidine deaminase confers sensitivity to capecitabine.
Morita T; Matsuzaki A; Kurokawa S; Tokue A
Oncology; 2003; 65(3):267-74. PubMed ID: 14657601
[TBL] [Abstract][Full Text] [Related]
31. The rational development of capecitabine from the laboratory to the clinic.
Pentheroudakis G; Twelves C
Anticancer Res; 2002; 22(6B):3589-96. PubMed ID: 12552961
[TBL] [Abstract][Full Text] [Related]
32. Clinical pharmacokinetics of capecitabine.
Reigner B; Blesch K; Weidekamm E
Clin Pharmacokinet; 2001; 40(2):85-104. PubMed ID: 11286326
[TBL] [Abstract][Full Text] [Related]
33. [Comparative studies on the antitumor activity of the fluorinated pyrimidines 5'-DFUR, tegafur, UFT and FUra on various murine tumors].
Miwa M; Eda H; Fukuda H; Fujimoto K; Ishitsuka H
Gan To Kagaku Ryoho; 1988 May; 15(5):1755-63. PubMed ID: 2967051
[TBL] [Abstract][Full Text] [Related]
34. Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil.
Sekido M; Fujita KI; Kubota Y; Ishida H; Takahashi T; Ohkuma R; Tsunoda T; Ishikawa F; Shibanuma M; Sasaki Y
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1127-1135. PubMed ID: 30972456
[TBL] [Abstract][Full Text] [Related]
35. Antiangiogenic effect of capecitabine combined with ginsenoside Rg3 on breast cancer in mice.
Zhang Q; Kang X; Yang B; Wang J; Yang F
Cancer Biother Radiopharm; 2008 Oct; 23(5):647-53. PubMed ID: 18999937
[TBL] [Abstract][Full Text] [Related]
36. Interferon alpha and 5'-deoxy-5-fluorouridine in colon cancer: effects as single agents and in combination on growth of xenograft tumours.
Laurent PL; Tevaearai HT; Eliason JF; Givel JC; Odartchenko N
Eur J Cancer; 1994; 30A(12):1859-65. PubMed ID: 7880618
[TBL] [Abstract][Full Text] [Related]
37. Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts.
Yamamoto S; Kurebayashi J; Kurosumi M; Kunisue H; Otsuki T; Tanaka K; Sonoo H
Cancer Chemother Pharmacol; 2001 Oct; 48(4):283-8. PubMed ID: 11710628
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and interaction with uridine phosphorylase of 5'-deoxy-4',5-difluorouridine, a new prodrug of 5-fluorouracil.
Ajmera S; Bapat AR; Stephanian E; Danenberg PV
J Med Chem; 1988 Jun; 31(6):1094-8. PubMed ID: 2967375
[TBL] [Abstract][Full Text] [Related]
39. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
Malet-Martino M; Martino R
Oncologist; 2002; 7(4):288-323. PubMed ID: 12185293
[TBL] [Abstract][Full Text] [Related]
40. Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues.
Mori K; Hasegawa M; Nishida M; Toma H; Fukuda M; Kubota T; Nagasue N; Yamana H; Hirakawa-YS Chung K; Ikeda T; Takasaki K; Oka M; Kameyama M; Toi M; Fujii H; Kitamura M; Murai M; Sasaki H; Ozono S; Makuuchi H; Shimada Y; Onishi Y; Aoyagi S; Mizutani K; Ogawa M; Nakao A; Kinoshita H; Tono T; Imamoto H; Nakashima Y; Manabe T
Int J Oncol; 2000 Jul; 17(1):33-8. PubMed ID: 10853015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
